An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.

In a world where weight loss struggles are increasingly ... by years of clinical research. Semaglutide and tirzepatide have demonstrated consistent success in helping individuals lose weight.

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Following her drastic weight loss she struggled with sagging skin and the dreaded droopy “Ozempic butt,” leaving her newly-taut body looking drab. So, to celebrate her svelte success ...

Utah Facial Plastics is transforming weight loss with Semaglutide and Tirzepitide, two proven treatments that help regulate ...

World-Renowned Bariatric Surgeon Dr. Amit Taggar Tampa's newest weight loss center offers advanced robotic bariatric surgery, free ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...